# Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma

> **NCT00418093** · PHASE2 · TERMINATED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 19 (actual)

## Conditions studied

- Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Cancer

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Oxaliplatin
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT00418093
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-09
- **Primary completion:** 2011-01
- **Final completion:** 2011-10
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** THe study was terminated early due to a lack of accural
- **Last updated:** 2014-06-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00418093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00418093, "Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00418093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*